Early use of a targeted budesonide for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have IgA nephropathy confirmed by a kidney biopsy within the last 3 months
- Your kidney function is at least 30% of normal (eGFR ≥ 30)
- You have significant protein in your urine (≥1 gram per day or a certain ratio)
- You have not used strong immune-suppressing drugs or steroids in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called Nefecon can help prevent IgA nephropathy (a kidney disease) from returning after your protein levels improve. You would take Nefecon or a placebo for a year while your doctors monitor your kidney health and urine protein levels.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
This trial tests whether adding probiotics to a standard treatment (budesonide, an enteric-coated steroid) can help reduce protein in the urine of people with IgA nephropathy. It aims to see if the combination is more effective than budesonide alone.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.